Real-world persistence data will be particularly important to guide efforts for shoring up the chronic market opportunity, e.g., via digital health support programmes, such as the Omada Health-Evernorth partnership [8]
CY-5, a novel GLP-1/GIP dual receptor agonist, was recently discovered by Liu et al., which showed efficacy in reducing serum lipids, LFTs, and biopsy-proven hepatic steatosis in an AMLN diet NAFLD mouse model [47]
Effects of the Sema + Cagrilintide Blend: Dual-Pathway Weight Loss: Investigated for the ability of combined GLP-1 and Amylin agonism to produce superior weight loss compared to monotherapy in rodent models
Furthermore, preclinical pharmacokinetic studies showed better C max , T max and AUC [13]
Every month there's data that comes out and says how many manufacturing projects were announced in the U.S